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Summary
 
Expression of the T cell antigen receptor (TCR) on the surface of thymocytes and mature T
cells is dependent on the assembly of receptor subunits into TCRs in the endoplasmic reticu-
lum (ER) and their successful traversal of the secretory pathway to the plasma membrane.
TCR subunits that fail to exit the ER for the Golgi complex are degraded by nonlysosomal
processes that have been referred to as “ER degradation”. The molecular basis for the loss of
the TCR CD3-
 
d
 
 and TCR-
 
a
 
 subunits from the ER was investigated in lymphocytes. For
CD3-
 
d
 
, we describe a process leading to its degradation that includes trimming of mannose
residues from asparagine-linked (N-linked) oligosaccharides, generation of ubiquitinated mem-
brane-bound intermediates, and proteasome-dependent removal from the ER membrane.
When either mannosidase activity or the catalytic activity of proteasomes was inhibited, loss of
CD3-
 
d
 
 was markedly curtailed and CD3-
 
d
 
 remained membrane bound in a complex with
CD3-
 
e
 
. TCR-
 
a
 
 was also found to be degraded in a proteasome-dependent manner with ubiq-
uitinated intermediates. However, no evidence of a role for mannosidases was found for TCR-
 
a
 
,
and significant retrograde movement through the ER membrane took place even when pro-
teasome function was inhibited. These findings provide new insights into mechanisms em-
ployed to regulate levels of TCRs, and underscore that cells use multiple mechanisms to target
proteins from the ER to the cytosol for degradation.
O ¯
 
T
 
he multi-subunit TCR is comprised of six distinct
type I transmembrane polypeptides that assemble in
 
the endoplasmic reticulum (ER)
 
1
 
 as an octameric complex.
On most T cells, these receptor subunits consist of clono-
typic TCR-
 
a/b
 
 
 
heterodimers in association with a set of
invariant subunits including heterodimers of CD3-
 
d
 
 
 
and -
 
e
 
,
and
 
 
 
CD3-
 
g
 
 
 
and -
 
e
 
, and a TCR-
 
z
 
 homodimer (1). In T
cells, cell surface expression of TCRs is dependent on the
proper assembly of complete TCRs in the ER, which then
traverse the secretory pathway to arrive at the plasma mem-
brane (1). Partial receptors lacking only 
 
z
 
 homodimers also
assemble and leave the ER. However, these are largely de-
graded in lysosomes (2). Other partial receptors and unas-
sembled subunits, except for 
 
z
 
, are retained in the ER from
where they are degraded with varying efficiencies by
poorly understood mechanisms that have been referred to
as “ER degradation”(3, 4). ER degradation is believed to
play a particularly prominent role in immature (CD4
 
1
 
CD8
 
1
 
) thymocytes undergoing selection in the thymus.
These cells express only 10% of the number of cell surface
TCRs as mature thymocytes despite adequate synthesis of
all TCR subunits. This low TCR expression occurs as a
consequence of as yet undefined posttranslational mecha-
nisms that include a relative block in egress of TCRs from
the ER and increased degradation of TCR components
from this organelle (5, 6).
Among the TCR subunits, TCR-
 
a
 
 and CD3-
 
d
 
 are par-
ticularly susceptible to degradation from the ER, whereas
CD3-
 
g
 
 and CD3-
 
e
 
 generally exhibit considerably longer
half-lives (3, 4, 7). The molecular basis for the selectivity of
targeting for degradation among receptor subunits is largely
 
1
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serum; CFTR, cystic fibrosis conductance regulator; CHX, cycloheximide;
dMNJ, deoxymannojirimycin; dMJ, deoxynojirimycin; ER, endoplasmic
reticulum; Glc, glucose; GlcNAc, 
 
N
 
-acetyl glucosamine; LCN, lactacys-
tin; LLM, LLnL, 
 
N
 
-acetyl-Leu-Leu-methioninal; 
 
N
 
-acetyl-Leu-Leu-nor-
leucinal; Man, mannose; Mg132, Z-Leu-Leu-Leu CHO.
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unknown; however, it has been shown that TCR-
 
a
 
 is
uniquely unstable as a transmembrane protein due to the
presence of two basic amino acids within its transmem-
brane domain (8, 9).
The modification of proteins with chains of ubiquitin is
well-established as an important and regulated means of
disposing of cytosolic and nuclear proteins by targeting for
degradation in 26S proteasomes (10, 11). Recently, how-
ever, there have been several reports implicating protea-
somes in the degradation of transmembrane and soluble
yeast (12–14) and mammalian (15–21) proteins that were
initially cotranslationally inserted into the ER. A well-stud-
ied example is that of MHC class I heavy chains, which,
like TCR subunits, are type 1 transmembrane proteins
with a single transmembrane domain. Newly synthesized
MHC class I heavy chains undergo rapid proteasomal deg-
radation in cells that express certain human cytomegalovi-
rus gene products, are defective in peptide transport into
the ER, or lack expression of 
 
b
 
2 microglobulin (19–21).
These MHC molecules are dislocated from the ER mem-
brane to the cytosol with the concomitant total removal of
N-linked oligosaccharides by a cytosolic 
 
N
 
-glycanase activ-
ity. Notably, this removal from the ER membrane occurs
independently of the catalytic activity of proteasomes.
These dislocated proteins are then degraded in the cytosol
in a proteasome-dependent manner, without evidence of
ubiquitinated intermediates. Based on these observations, as
well as others involving a mutant form of a soluble luminal
yeast protein (13), models have been proposed for the deg-
radation of ER proteins in which the proteins are first dis-
located into the cytosol from whence they are degraded by
proteasomes (20, 22–24).
ER forms of the multi-membrane spanning cystic fibro-
sis conductance regulator (CFTR) are also degraded by
proteasomes, in this case with the generation of ubiquiti-
nated intermediates (15, 16). It has been speculated that
misfolded forms of this complex protein are recognized as
such by enzymes of the ubiquitin-conjugating system and
are therefore targeted for destruction. However, no infor-
mation is available as to the subcellular location of ubiquit-
inated CFTRs, nor is it known whether CFTRs are dislo-
cated from ER membranes before ubiquitination.
In this study, we have evaluated the degradation of mu-
rine CD3-
 
d
 
 and TCR-
 
a
 
 from the ER in T lymphocytes,
which continually synthesize and degrade these subunits (3,
4, 7). CD3-
 
d
 
 has a core molecular weight of 16 kD; the
addition of three N-linked oligosaccharide chains results in
its migration at 
 
z
 
26 kD by SDS-PAGE (25). This protein
has a luminal domain of 
 
z
 
79 amino acids and an intracyto-
plasmic domain of 46 amino acids that includes three
lysines. The TCR-
 
a
 
 subunit has four sites of 
 
N
 
-glycosyla-
tion and, in most T cells, forms disulfide-linked hetero-
dimers with the TCR-
 
b
 
 subunit after its cotranslational
membrane insertion. TCR-
 
a
 
 
 
has a small cytoplasmic do-
main of five amino acids, none of which are lysines. As pre-
viously mentioned, the transmembrane domain of TCR-
 
a
 
includes two basic amino acids (Arg and Lys) that may de-
stabilize this molecule in the ER, perhaps functioning as an
inefficient stop-transfer signal (8, 9). We now report that
both CD3-
 
d
 
 and TCR-
 
a
 
 are ubiquitinated and are de-
graded from the ER in a proteasome-dependent manner and
that for CD3-
 
d
 
, removal from the ER requires the catalytic
activity of proteasomes and the activity of mannosidases.
 
Materials and Methods
 
Cells and Reagents.
 
Thymi from C57Bl/6 
 
3
 
DBA/2 mice
that had been interbred for 20 generations were provided by
Astrid Eder (National Cancer Institute, Bethesda, MD). 21.2.2
cells (26) and BW5147 cells (27) were maintained in complete
medium as previously described (26). COS-7 cells were main-
tained and transfected as previously described (28). Anti-CD3-
 
d
 
(R9; reference 29), affinity-purified anti-ubiquitin (anti-Ub; ref-
erence 30), 2C11 (31), #125 (7), and H28-710 (32) have all been
previously described. Reagents included the following: Z-Leu-
Leu-Leu-CHO (MG132; Proscript, Cambridge, MA), 50 
 
m
 
M;
 
N
 
-acetyl-Leu-Leu-norleucinal (LLnL) and N-Acetyl-Leu-Leu-
methioninal (LLM; both from Boehringer Mannheim, Indianap-
olis, IN), 100 
 
m
 
M; lactacystin (LCN), 50 
 
m
 
M; NH
 
4
 
Cl, 20 mM;
cycloheximide (CHX), 100 
 
m
 
M; deoxymannojirimycin (dMNJ;
Sigma Chemical Co., St. Louis, MO), 1 mM (see Fig. 4, 
 
E
 
 only)
or 2 mM; and deoxynojirimycin (dNJ; Sigma Chemical Co.), 2
mM. Cells were preincubated with DMNJ or DNJ for 2 h at
37
 
8
 
C before the initiation of experiments.
 
Experimental Techniques.
 
For “pulse-chase” metabolic labeling
experiments, cells were incubated at 37
 
8
 
C for 20 min in me-
thionine-free medium before labeling with Tran
 
35
 
S-label (ICN
Radiochemicals, Costa Mesa, CA) at 1 mCi/ml (thymocytes) or
300 
 
m
 
Ci/ml (cell lines). After labeling, cells were washed and re-
suspended in complete medium with the indicated additions.
Cells were lysed and immunoprecipitates were washed in buffers
containing Triton X-100 as previously described (33), except that
0.1% SDS was added to the wash buffer in all immunoprecipitates
except those with 2C11, and 0.1% SDS was added to the lysis
buffer in experiments in which samples were immunoprecipitated
with anti–TCR-
 
a
 
. Except where noted, 1–2 
 
3 
 
10
 
7 
 
cells were an-
alyzed in each immunoprecipitation. Resolution of samples by
reducing or by two-dimensional nonreducing/reducing SDS-
PAGE, immunoblotting, and autoradiography were all carried
out as previously described (30, 34). Except for Fig. 1 
 
C
 
, which
was developed using enhanced chemiluminescence, all other im-
munoblots were developed using 
 
125
 
I Protein A (ICN Radio-
chemicals). For subcellular fractionation experiments, cells were
resuspended in 0.25 M sucrose, 10 mM triethanolamine, and 1
mM EDTA, pH 7.4, for 10 min at 4
 
8
 
C followed by 15 passages
through a 27-gauge needle. The material was subject to two se-
quential 5 min 1,000 
 
g
 
 spins to remove unbroken cells and nuclei.
For separation of cytosolic and membrane fractions, supernatants
from the 1,000 
 
g
 
 spin were pelleted at 100,000 
 
g
 
 for 1 h at 4
 
8
 
C.
Supernatants (cytosolic fractions) were directly immunoprecipi-
tated (see Fig. 4) or immunoprecipitated after addition of lysis
buffer (see Figs. 7 and 8). The buffer conditions were determined
to have no effect on the ability of antibodies to immunoprecipi-
tate TCR components. The pellet (membrane fraction) was lysed
in Triton X-100 lysis buffer and immunoprecipitated. In protease
protection assays the supernatant from the 1,000 
 
g
 
 spin was
treated with proteinase K at a final concentration of 100 
 
m
 
g/ml at
4
 
8
 
C, which was neutralized with 2 mM PMSF. All quantitation
was carried out on gels analyzed using a Storm 820 PhosphorIm-
ager and ImageQuant software (Molecular Dynamics, Inc., Sunny- 
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vale, CA). Coupled in vitro transcription and translation of murine
CD3-
 
d
 
 using TNT rabbit reticulocyte lysate (Promega, Madison,
WI) and 
 
35
 
[S]methionine (Amersham Corp., Arlington Heights,
IN) was carried out as per the manufacturer’s instructions. Treat-
ment with 
 
N
 
-glycanase (PNGase F; New England Biolabs, Inc.,
Beverly, MA) at 500 U/
 
m
 
l was carried out on washed immuno-
precipitates using conditions specified by the manufacturer.
 
Results
 
CD3-
 
d
 
 Is Ubiquitinated and Degraded by Proteasomes.
 
To determine if proteasomes play a role in degradation of
CD3-
 
d
 
,
 
 
 
unfractionated thymocytes were subject to pulse-
chase metabolic labeling followed by immunoprecipitation
with an anti-peptide rabbit polyclonal antibody
 
 
 
that recog-
nizes the cytoplasmic domain of CD3-
 
d
 
 (anti–CD3-
 
d
 
; ref-
erence 29). Newly synthesized CD3-
 
d
 
 was found to be
rapidly degraded (Fig. 1 
 
A
 
); however, a peptide-aldehyde
that inhibits proteasome function, LLnL (35), blocked its
degradation, whereas an inhibitor of lysosome function,
NH
 
4
 
Cl, was significantly less effective. A second potent
peptide-aldehyde proteasome inhibitor, MG132 (36), as
well as LCN, a chemically unrelated and highly specific
proteasome inhibitor (37), both also markedly inhibited
loss of CD3-
 
d
 
 (Fig. 1 
 
B
 
). 
To establish whether CD3-
 
d
 
 undergoes ubiquitination
in thymocytes, anti–CD3-
 
d
 
 immunoprecipitates were im-
munoblotted with anti-Ub antibodies capable of detecting
low levels of multi-ubiquitinated proteins (reference 30,
Fig. 1 
 
C
 
). Consistent with CD3-
 
d
 
 ubiquitination, in cells
treated with the proteasome inhibitor LLnL discrete species
as well as a higher molecular weight “smear” was easily de-
tected in anti–CD3-
 
d
 
 immunoprecipitates but not in im-
munoprecipitates with control antiserum (CA). These were
not detected in cells incubated without LLnL, indicating
that these species are normally efficiently degraded by pro-
teasomes.
To further assess proteasomal degradation of CD3-
 
d
 
 we
turned to 21.2.2 cells (26). This cell line is a variant of the
T cell hybridoma 2B4 (38) distinguished by its failure to
express any form of TCR-
 
b
 
. This cell line is also deficient
in expression of the 2B4-specific TCR-
 
a chain, but it does
express TCR-a chains derived from BW5147, the fusion
partner used in the generation of 2B4 (27). Because 21.2.2
Figure 1. Proteasomal degradation and ubiquitination of CD3-d in
thymocytes. (A and B) Thymocytes from 12- (A) or 6-wk-old (B) mice
were preincubated with the indicated treatments for 1 h at 48C before la-
beling for 20 (A) or 30 min (B) at 378C with [35S]methionine followed by
a chase in complete medium with the indicated additions still present.
CD3-d was immunoprecipitated (IP) from cell lysates using an anti–CD3-d
antiserum raised in rabbit (also known as R9; reference 29) and samples
were resolved by SDS-PAGE under reducing conditions followed by au-
toradiography. The position of CD3-d is indicated. The minor 16-kD
band seen at chase points from proteasome-treated samples in B may rep-
resent a small amount of deglycosylated CD3-d. (C) Thymocytes were
incubated at 378C as indicated, followed by immunoprecipitation of cell
lysates with either anti–CD3-d or CA. Immunoblotting (IB) was with
polyclonal anti-Ub as previously described (30).
Figure 2. Proteasomal degradation and ubiquitination of CD3-d in a T
cell line. (A) [35S]methionine labeling of 21.2.2 cells was carried out for
20 min as in Fig. 1 followed by a 3-h chase. Immunoprecipitation was
with anti–CD3-d. (B) 21.2.2 cells were treated as in Fig. 1 C, lysates were
immunoprecipitated with either anti–CD3-d or CA, and membranes
were immunoblotted with anti-Ub. (C) An anti–CD3-d immunoprecipi-
tate from LLnL-treated 21.2.2 cells was heated to 958C in SDS-PAGE
sample buffer containing 0.5% dithiothreitol for 5 min and then diluted
into 500 ml of Triton X-100 lysis buffer. The sample was divided, reim-
munoprecipitated with either anti–CD3-d or CA, and immunoblotted
with anti-Ub.838 Degradation of T Cell Receptor Subunits
cells lack TCR-b, TCRs do not assemble, and CD3-d re-
mains in the ER from whence it is degraded (33). When
pulse-chase metabolic labeling was carried out on these
cells, LLnL and MG132 each inhibited degradation of
newly synthesized CD3-d, while a closely related peptide-
aldehyde that is ineffective in blocking proteasome func-
tion, LLM (35), did not substantively affect CD3-d loss
(Fig. 2 A). As expected for this cell line, NH4Cl failed to
block CD3-d loss (Fig. 2 A), and LCN was as effective as
LLnL and MG132 (data not shown).
As with thymocytes, inhibition of proteasome function
also resulted in an accumulation of specifically immunopre-
cipitated ubiquitinated species in 21.2.2 (Fig. 2 B). In Fig. 2
B immunoprecipitates were washed under conditions that
minimize coimmunoprecipitation of other proteins with
CD3-d. To verify that CD3-d itself was being ubiquiti-
nated, anti-CD3-d immunoprecipitates from LLnL-treated
cells were denatured in SDS-PAGE sample buffer and then
reimmunoprecipitated (Fig. 2 C). Only the sample speci-
fically reimmunoprecipitated with anti–CD3-d recovered
ubiquitinated material.
Oligosaccharide Processing and CD3-d Degradation. Accom-
panying the proteasome-dependent loss of CD3-d (Figs. 1
and 2) is a drop in molecular weight suggestive of the post-
translational action of mannosidases, which are present
both in the ER and cis-Golgi. Mannosidases are responsible
for the trimming of N-linked oligosaccharides after the
rapid cleavage of the three glucose residues from the cotrans-
lationally added Glc3Man9GlcNAc2 structure (Glc, glucose;
Man, mannose; GlcNAc, N-acetyl glucosamine; reference
39). The resultant Man5GlcNAc2 may be further processed
to generate complex carbohydrates in the medial- and trans-
Golgi. To ascertain whether the change in migration is due
to mannose trimming, cells were treated with dMNJ, a
specific inhibitor of ER and Golgi mannosidases. As is evi-
dent, the change in migration of CD3-d during the chase
was largely abrogated by this treatment (Fig. 3 A). Strik-
ingly, however, dMNJ also markedly inhibited the loss of
CD3-d during the chase. This effect was specific for inhibi-
tion of mannosidases, as a closely related compound, dNJ,
which inhibits glucosidases but not mannosidases, affected
the migration of CD3-d but was ineffective in altering its
fate (Fig. 3, B and C). Results similar to those obtained
with dNJ were obtained with another glucosidase inhibi-
tor, castanospermine (data not shown). As is evident (Fig.
3, B and C), the ability of dMNJ to inhibit loss of CD3-d
was similar in magnitude to effects seen with LLnL; and ex-
posure of cells to the two together was not additive (data
not shown). This suggests that the proteasome inhibitor
and mannosidase inhibitor are functioning on the same
population of CD3-d molecules. Moreover, the half-life
CD3-d was prolonged by either LLnL or dMNJ when this
TCR subunit was expressed transiently in COS-7 cells
(data not shown), indicating that the effects seen do not re-
quire other T cell–specific proteins.
Subcellular Localization of CD3-d. Subcellular fractionation
was carried out to determine whether the CD3-d that ac-
cumulates when proteasome function is inhibited is mem-
brane-bound or cytosolic. After a 20 min labeling with
[35S]methionine and a chase in medium without [35S]me-
thionine (Fig. 4 A, lanes 1–4), cells were broken by me-
chanical shearing without detergent and fractionated into
residual unbroken cells and nuclei (U), membranes (M), and
cytosol (C) (Fig. 4 A, lanes 5–10), and immunoprecipitated
with anti–CD3-d. CD3-d was not found in the cytosolic
fractions of cells. Instead, CD3-d localized to the mem-
brane fraction, with LLnL-treated cells exhibiting greater
levels of membrane-associated CD3-d, commensurate with
the increased amount of CD3-d present at the end of the
chase (Fig. 4 A, lanes 1–4). To verify that CD3-d, if
present, could be immunoprecipitated from the cytosolic
fraction by anti–CD3-d, CD3-d that had been translated in
vitro in rabbit reticulocyte lysate without microsomes was
mixed with the cytosolic fraction. As shown (Fig. 4 B), this
exogenously added material could be specifically immuno-
precipitated from the cytosolic fraction with anti–CD3-d.
CD3-e is the only nonglycoprotein of the three CD3
subunits (1). At an early stage in the assembly of the octo-
meric TCR complex, CD3-d and CD3-g each dimerize
with CD3-e through their luminal domains. Dimerization
with CD3-d or CD3-g allows heterodimers containing
CD3-e  to be immunoprecipitated by 2C11, a monoclonal
antibody that recognizes a conformation-dependent luminal
epitope on CD3-e (7, 31). The association of CD3-e with
CD3-d and their coimmunoprecipitation with 2C11 was
used to further assess the localization of CD3-d. As is evi-
dent in both LLnL-treated and untreated samples (Fig. 4
C), the large majority of membrane-bound CD3-d is im-
Figure 3. Oligosaccharide processing and degradation of CD3-d. (A
and B) 21.2.2 cells were labeled with [35S]methionine for 20 min at 378C
as in Fig. 2 A and were chased as indicated. Immunoprecipitation was
with anti–CD3-d. (C) Quantitation of data from B.839 Yang et al.
munoprecipitated with 2C11. This demonstrates that CD3-d
salvaged from degradation is largely bound to CD3-e.
The results presented in Fig. 4, A and C strongly suggest
that, when its degradation is inhibited, CD3-d accumulates
in ER membranes in a native configuration. To establish
the topological orientation of CD3-d with certainty, pro-
tease-protection studies were carried out. In these experi-
ments 21.2.2 cells were labeled with [35S]methionine, and
after a 3-h chase cells were broken by mechanical shearing
and nuclei and residual unbroken cells were removed. The
resultant postnuclear supernatant, consisting of cytosol and
membrane-bound organelles, was subject to proteinase K
digestion. Such treatment will degrade portions of proteins
that are exposed to the cytosol, but leave protected trans-
Figure 4. Subcellular localization of CD3-d. (A) 21.2.2 cells were labeled with [35S]methionine for 20 min followed by a 2.5-h chase. In lanes 1–4,
cells were lysed in Triton X-100 lysis buffer directly. In lanes 5–10, cells from the 2.5-h chase were broken open by mechanical shearing without deter-
gent, as described in Materials and Methods, followed by removal of unbroken cells and nuclei (U) and separation of cytosolic (C) and membrane (M)
fractions. Immunoprecipitation was with anti–CD3-d. The amount of material used in the whole cell samples (lanes 1–4) was 1.5 3 107 cells/lane; 3 3 107
cells were subject to fractionation (lanes 5–10). (B) CD3-d translated in rabbit reticulocytes in vitro and labeled using [35S]methionine was added to cyto-
sol prepared as in A and immunoprecipitated with either CA or anti–CD3-d. (C) 21.2.2 cells were labeled for 20 min and chased either in the absence or
presence of LLnL for 3 h. Membrane (M) and cytosol (C) fractions were prepared as in A. Only half of the residual unbroken cells and nuclei (U) were
analyzed in this experiment. Lysates were subject to sequential immunoprecipitation with 2C11(top) followed by anti–CD3-d (bottom). In pulse-chase ex-
periments CD3-e labels poorly and is not well-visualized (33). (D) 21.2.2 cells were labeled for 20 min with [35S]methionine, then either treated or not
with LLnL for 1 h at 48C before a 3-h chase in the presence or absence of LLnL. Cells were then broken as in A. After removal of nuclei and unbroken
cells, supernatants were divided and treated on ice either without further treatment, with the addition of proteinase K, or first treated with Triton X-100
(0.5%) followed by the addition of proteinase K as indicated. After 1 h at 48C, PMSF was added to inactivate proteinase K, and Triton X-100 (0.5%) was
then added to samples that had not been pretreated with this detergent. All samples were immunoprecipitated with 2C11. The positions of full length
CD3-d and of CD3-d with a cleaved cytosolic tail are indicated. (E) 21.2.2 cells were subject to pulse-chase metabolic labeling as in C in the presence or
absence of dMNJ. Cells were broken, and after removal of unbroken cells and nuclei supernatants were subject to proteinase K digestion and immuno-
precipitation with 2C11 as in D. (F) 21.2.2 cells were incubated for 3 h either with or without LLnL. 1.5 3 107 cells were lysed directly in Triton X-100
lysis buffer (W), while the rest (5 3 107) were fractionated as in A followed by immunoprecipitation with anti–CD3-d. Fractionated LLnL-treated sam-
ples were also immunoprecipitated with CA (lanes 9–11). Immunoblotting was with anti-Ub.840 Degradation of T Cell Receptor Subunits
membrane and luminal domains intact. Since the epitope
recognized by anti–CD3-d is cytosolic and, as expected,
lost on treatment with proteinase K (data not shown), we
took advantage of the luminal epitope recognized by 2C11
to immunoprecipitate residual CD3-d after proteinase K
digestion (Fig. 4, D and E). As predicted for CD3-d in its
native topological membrane orientation, its z4-kD cyto-
solic domain was degraded by proteinase K, while the lu-
minal and transmembrane domains of CD3-d were largely
protected. As expected, solubilization of membranes with
Triton X-100 before exposure to proteinase K abrogated
this protection. Importantly, increased levels of CD3-d
were protected in cells in which CD3-d degradation was
prevented by inhibition of either proteasome function (Fig.
4 D) or mannosidase activity (Fig. 4 E). Also, the amount
of material remaining after protease treatment (as compared
with nondigested samples) was similar in cells in which
proteasome or mannosidase activity was inhibited and in
untreated samples. This establishes that when either protea-
some function or mannosidase activity is inhibited, the
CD3-d that remains is still membrane-embedded in its na-
tive topological orientation.
To determine the location of ubiquitinated CD3-d, anti-
Ub immunoblotting of immunoprecipitates from fraction-
ated cells was carried out (Fig. 4 F). Although some ubiq-
uitinated CD3-d was found in the cytosolic (C) fraction
from LLnL-treated cells, the majority was membrane-
bound (M; Fig. 4 F). Thus, it is apparent that ubiquitina-
tion of CD3-d takes place while still in the ER membrane.
Degradation of TCR-a: Involvement of Proteasomes but not
Mannosidases. TCR-a chains are products of genes that
undergo somatic rearrangement. In most cells TCR-a
forms disulfide-linked dimers with TCR-b, also a product
of a rearranged gene. The membrane proximal portion of
the intraluminal domain (extracellular domain) and the en-
tire transmembrane and cytoplasmic segments of mouse
TCR-a are derived from a constant region that is invariant
among TCR-a’s in different cells (40). The TCR-a trans-
membrane segment is remarkable in having two charged
amino acids (Lys and Arg), and its short cytoplasmic do-
main has no Lys residues (41). Recent studies in non-T
cells have provided evidence for proteasome-independent
dislocation of TCR-a from the ER to the cytosol accom-
panied by removal of its N-linked sugars (42, 43), similar to
that observed for MHC class I (19–21), without evidence
of accompanying ubiquitination. To assess the degradation
Figure 5. Degradation of TCR-a in BW5147. 35S-labeling of
BW5147 cells and chase was carried out as described in Figure 2. Samples
were lysed in Triton X-100 lysis buffer with 0.1% SDS to decrease non-
specific binding. Anti–TCR-a ( A  and C) immunoprecipitates were
washed in 0.1% Triton X-100, 0.1% SDS and resolved by SDS-PAGE
under reducing conditions (A) or on two-dimensional nonreducing/re-
ducing gels (C) followed by autoradiography. The longer exposure of the
left upper panel of C is to demonstrate the position of disulfide-linked
TCR-a/b dimers. B shows a quantitation of the experiment in A. Quan-
titation was by Storm 820 PhosphorImager using ImageQuant software.
Figure 6. Degradation of TCR-a in 21.2.2 cells. (A) Cells were la-
beled and chased in cold medium for the indicated times followed by se-
quential immunoprecipitation with anti–TCR-a (upper panel) followed
by anti–CD3-d (lower panel). (B) Cells were labeled and chased as indi-
cated and immunoprecipitates were treated with or without N-glycanase.
Positions of TCR-a, partially and fully deglycosylated TCR-a, and im-
munoreactive degradation products are indicated.841 Yang et al.
of TCR-a we evaluated BW5147, the fusion partner used
in the generation of T cell hybridomas such as 2B4 (38).
This well-characterized thymoma expresses TCR-a and
TCR-b but not CD3-d (44). Using a monoclonal anti–
TCR-a antibody that recognizes a constant region intralu-
minal epitope, newly synthesized TCR-a was found to be
rapidly degraded (Fig. 5, A and B). LLnL markedly inhib-
ited TCR-a loss, and this was accompanied by increased
density both above and below TCR-a (Fig. 5 A), perhaps
representing ubiquitination and partial degradation, respec-
tively (similar results were obtained using LCN; data not
shown). However, dMNJ had minimal effects on loss of
this receptor subunit (Fig. 5, A and B). To ascertain the ex-
tent to which TCR-a is disulfide-linked to TCR-b, samples
were resolved by two-dimensional nonreducing/reducing
SDS-PAGE (Fig. 5 C). The large majority of TCR-a, in-
cluding most that was salvaged by LLnL, was found not to
be disulfide-linked to TCR-b. The findings obtained in
BW5147 cells were verified in 21.2.2 cells (Fig. 6 A), where
dMNJ inhibited degradation of CD3-d but not TCR-a. In
21.2.2 and BW5147 a minor band above the predominant
form of TCR-a is often distinguished, which may reflect ex-
pression from a second BW-specific TCR-a allele in these
cells (45). Inhibition of TCR-a degradation was accompanied
by the appearance of lower molecular species of 14–30 kD
(Fig. 6, A and B), which unlike full-length TCR-a, were
unaffected by treatment with N-glycanase (Fig. 6 B) and
which were immunoreactive with anti–TCR-a by immu-
noblotting (data not shown). These therefore likely repre-
sent incompletely proteolyzed deglycosylated TCR-a.
Proteasome-independent Retrograde Movement of TCR-a.
The location of TCR-a in T cells was assessed by separa-
tion of membrane and cytosolic fractions. In BW5147 as
well as 21.2.2 cells, the large majority of TCR-a that accu-
mulated was found in the membrane fraction (Fig. 7, A and
B). In some samples treated with LLnL, more rapidly mi-
grating forms, consistent with deglycosylation, are dispro-
portionately represented in the cytosolic fraction. The to-
pological orientation of TCR-a was assessed by proteinase
K digestion of cells that had been broken open by mechan-
ical shearing (Fig. 8). In contrast to CD3-d, where a similar
proportion of material was protected in samples treated
with or without proteasome inhibitors, a substantially
smaller percentage of the TCR-a was protected in samples
in which proteasome function was inhibited as compared
with samples not exposed to proteasome inhibitors (Fig.
8 A). Strikingly, loss of full length TCR-a was accompa-
nied by the appearance of a discrete lower molecular
weight immunoreactive band of z23 kD (Fig. 8 A). That
this is a fragment of TCR-a and not an associated protein
was established by heating of immunoprecipitates to 958C
in SDS sample buffer under reducing conditions and reim-
munoprecipitation with anti-TCR-a (Fig. 8 C). As is evi-
dent, this 23-kD band was recovered with the same effi-
ciency as full length TCR-a. A similar fragment was
visualized when broken cells were digested with trypsin in-
stead of proteinase K (data not shown). Since the 23-kD
fragment drops from the predicted molecular weight of
glycosylated TCR-a, it is likely to also be glycosylated. In
fact, treatment with N-glycanase resulted in a drop in mo-
lecular weight consistent with at least one N-linked oli-
gosaccharide (data not shown).
Figure 7. Subcellular localiza-
tion of TCR-a. BW5147 (A) or
21.2.2 cells (B) were labeled and
chased for the indicated times
followed by fractionation of cells
from the chase points as described
in Fig. 4 into membrane (M) and
cytosol (C) fractions and immu-
noprecipitation with anti–TCR-a
(A) or anti–TCR-a followed by
anti–CD3-d (B). Unfractionated
cells from the pulse and chase are
indicated by W. The number of
unfractionated cell equivalents
represents 15% of the number that
were subject to fractionation.
Figure 8. Protection of TCR-a in BW5147 cells. (A) Metabolically la-
beled cells were subject to a 2.5-h chase followed by breakage by me-
chanical shearing and treatment with proteinase K as described in Fig. 4.
Triton X-100 lanes indicate samples that were detergent solubilized be-
fore exposure to proteinase K. Immunoprecipitates from aliquots of cells
that were not subject to breakage by mechanical shearing but instead di-
rectly lysed in Triton X-100 from the pulse and chase time points are
shown in B. (C) To insure that the z23-kD band indicated by the aster-
isk represented a fragment of TCR-a and not an associated protein, a
proteinase K-treated sample was immunoprecipitated with anti–TCR-a
and half of the sample was denatured as described in Fig. 2, followed by
reimmunoprecipitation with additional anti–TCR-a. Note that the pro-
teinase K-dependent band (asterisk) persisted, whereas other species above
TCR-a were not reimmunoprecipitated. (D) Cells were labeled with
[35S]methionine in the absence of LLnL and then a 2-h chase was carried
out either in the presence or absence of LLnL. This was followed by pro-
teinase K digestion. 842 Degradation of T Cell Receptor Subunits
To assess whether this partially protected form of TCR-a
represents material that never fully traversed the ER mem-
brane, or if this reflects ongoing removal of TCR-a that
had been initially fully translocated into the ER, TCR-a
was labeled in the absence of LLnL and chased in its pres-
ence or absence. As can be seen in Fig. 8 D, a small amount
of this partially protected TCR-a was present at the end of
the pulse (lane 2); however, the amount detected clearly
increased when LLnL was present during the chase. This
indicates that TCR-a that had fully translocated across the
ER membrane undergoes partial retrotranslocation, result-
ing in the retention of a discrete form of TCR-a within
the ER lumen/membrane. This partial retrotranslocation
occurs independent of the activity of proteasomes. How-
ever, to complete the removal/degradation of TCR-a
from the ER membrane, as is the case with CD3-d, protea-
some activity is required.
Ubiquitination of TCR-a. The smearing seen above
TCR-a in lanes from LLnL-treated cells in Figs. 5 and 6 is
suggestive of ubiquitination. However, recently published
studies in which TCR-a was expressed in non-T cells
failed to reveal evidence for this modification (42, 43). To
assess whether ubiquitinated forms of TCR-a were being
generated in T cells, anti-Ub immunoblotting was carried
out on 21.2.2 cells. Similar to CD3-d, specifically immu-
noprecipitated ubiquitinated species were, in fact, detected
in the presence of the proteasome inhibitor LLnL (Fig. 9
A). These species were detected both in the cytosolic and
membrane compartments. Confirmation that these repre-
sent ubiquitinated TCR-a was obtained by dissociation of
samples in SDS and reimmunoprecipitation with anti–
TCR-a (data not shown). Since TCR-a, unlike CD3-d,
has no lysine residues that are normally exposed to the cy-
tosol (25, 41), ubiquitination of this subunit is either occur-
ring on residues that have become exposed to the cytosol
after the initiation of retrograde movement or is taking
place on luminal residues. However, as there is no evidence
for luminal ubiquitin-conjugating enzymes, the latter possi-
bility seems unlikely. To evaluate this, anti-Ub immuno-
blotting was carried out on samples that had been digested
with proteinase K. As is evident in Fig. 9 B, ubiquitin at-
tached to TCR-a was largely removed with proteinase K,
indicating that the lysines to which ubiquitin has been at-
tached on TCR-a are in the cytosol. It is therefore appar-
ent that, for TCR-a, initiation of retrograde movement
out of the ER precedes ubiquitination.
Discussion
Pathways to Proteasomal Degradation. Recent findings have
led to the emergence of models for degradation of trans-
membrane and soluble luminal proteins from the ER
where fates are largely decided by proteasome-independent
retrotranslocation from the ER to the cytosol through pro-
tein conducting channels followed by proteasomal degrada-
tion (20, 22–24). For MHC class I heavy chains (20) and
for a mutant form of a yeast luminal protein, carboxypepti-
dase y (46), it has been proposed that newly synthesized pro-
teins associate with the Sec61 translocon complex which
then facilitates their movement back into the cytosol. In
the case of retrotranslocation of MHC class I heavy chains,
this is accompanied by complete removal of N-linked oli-
gosaccharides, without evidence of ubiquitinated interme-
diates (19–21).
This study reveals that, in T cells, components of the
TCR are also degraded from the ER as a consequence of
pathways that terminate in proteasomes. Our evaluation of
CD3-d and TCR-a illuminates novel aspects of these deg-
radative pathways and underscores that, although cytosolic
proteasomes are likely a final destination for a large number
of proteins, the mechanisms involved in targeting for pro-
teasomal degradation vary significantly. Strikingly, even be-
tween two normal components of the TCR, the route and
the determining factors leading to degradation differ. TCR-a
undergoes partial retrograde movement regardless of pro-
teasome activity, with a 23-kD glycosylated fragment re-
maining sequestered within the ER when proteasome func-
tion is inhibited. The partial retrotranslocation of TCR-a
in the absence of proteasome function should be compared
with results obtained with MHC class I and more recent
studies in which TCR-a was overexpressed ectopically in
nonlymphoid cells (42, 43). In these instances complete re-
moval from the ER membrane occurred even when pro-
teasome function was inhibited. Further distinguishing our
findings from the aforementioned examples is the existence
of ubiquitinated membrane-associated TCR-a. In contrast
to TCR-a, the large majority of CD3-d retains its native
transmembrane location when proteasome function is in-
hibited. Thus, proteasome function is required both for de-
tectable retrograde movement and destruction of this TCR
subunit. Moreover, it is evident that there is a requirement
for cellular mannosidase activity in proteasome-dependent
CD3-d degradation. As with TCR-a, CD3-d also under-
goes ubiquitination while still associated with the ER
membrane.
When assessing differences between TCR-a and CD3-d
that might account for their relative susceptibilities to pro-
Figure 9. Ubiquitination of
TCR-a in BW5147. (A) Cells
were treated with or without
LLnL as indicated and fraction-
ated as described for Fig. 4. 106
cells were used in the whole cell
lysate lanes (W), and 5 3 107
cells were fractionated into cyto-
sol and membrane fractions.
Lysis and washing of immuno-
precipitates was in buffer supple-
mented with 0.1% SDS. Immu-
noblotting was with anti-Ub. (B)
LLnL-treated cells were broken
and treated with or without pro-
teinase K followed by immuno-
precipitation and anti-Ub immu-
noblotting.843 Yang et al.
teasome-independent retrotranslocation, the nature of their
transmembrane segments must be considered. CD3-d has a
single acidic residue within its transmembrane domain, a
feature common to all of the invariant TCR components
(1). TCR-a, on the other hand, has two bulky basic amino
acids that have been postulated to contribute to its inherent
instability as a transmembrane protein (8, 9). Because of
this, it is reasonable to speculate that the relatively hydro-
philic nature of TCR-a’s transmembrane domain has the
potential to facilitate movement into and through protein-
conducting channels that mediate retrograde movement.
Whether or not this is a major factor in determining sus-
ceptibility to retrograde movement will require further
evaluation.
Mannosidase Activity and Degradation from the ER.
Branch chain N-linked oligosaccharides are cotranslation-
ally added to luminal asparagine residues of proteins as
Glc3Man9GlcNAc2 (39). The three terminal Glc residues
are generally rapidly cleaved in the ER, and ER and cis-
Golgi mannosidases carry out trimming of these “high
mannose” chains. This trimming involves removal of four
of the mannose residues generating Man5GlcNAc2 before
further processing in the Golgi complex to “hybrid” and
“complex” chains (39). For a number of proteins, oligosac-
charide processing plays important roles in ER “quality
control”. This has been analyzed predominantly with re-
gard to removal of glucose residues in calnexin- and calreti-
culin-mediated folding in the ER (47). Previous evidence
of a role for mannosidase activity in determining the fate of
proteins in the ER was limited to a study in which yeast
pre-pro-a factor was expressed ectopically in mammalian
cells (48), and more recent work on mutant a1-antitrypsin
(49). Both pre-pro-a factor and a1-antitrypsin are luminal
proteins without membrane anchors. Our results establish a
previously unappreciated role for mannosidase activity in
targeting a normal transmembrane protein, CD3-d, for
proteasomal degradation. They also demonstrate that man-
nosidases and proteasomes function along the same path-
way leading to destruction of this receptor subunit. When
21.2.2 cells were treated with tunicamycin, which blocks
the addition of N-linked oligosaccharides to proteins, non-
glycosylated CD3-d was rapidly degraded in a proteasome-
dependent manner, and, in COS-7 cells, CD3-d in which
the three sites of N-glycosylation were mutated was de-
graded rapidly (our unpublished observations). This sug-
gests that N-linked oligosaccharides in which mannose res-
idues have not been trimmed stabilize CD3-d. This could
occur by enhancing the association of CD3-d with the
more stable CD3-e. Arguing against this possibility are the
findings that trimmed and untrimmed CD3-d both coim-
munoprecipitate with anti-CD3-e, and that degradation of
CD3-d in COS-7 cells is also inhibited by dMNJ.
Man9GlcNAc2 species undergo cycles of reversible mono-
glucosylation (47). Since the carbohydrate-binding luminal
chaperones calnexin and calreticulin preferentially associate
with monoglucosylated oligosaccharides, interactions with
these proteins could stabilize CD3-d in which mannose res-
idues have not been trimmed. However, CD3-d does not
associate with calreticulin (50) and we and others have
found that the glycosylation state of CD3-d does not sub-
stantially affect its association with calnexin (51 and our un-
published observations). Although we can not exclude with
certainty that differences in the nature of calnexin interac-
tions explain the protective effects of mannosidase inhibi-
tors, we are left to consider that other, as yet to be charac-
terized, carbohydrate-binding “chaperones” play a role in
stabilization of untrimmed CD3-d.
Ubiquitination and Proteasomes in Degradation from the
ER. Ubiquitinated CD3-d and TCR-a are easily de-
tected when proteasome function is inhibited. Ubiquiti-
nated CD3-d is primarily membrane-associated, whereas
ubiquitinated TCR-a is found to a similar extent in both
membranes and cytosol. A model integrating ubiquitina-
tion with retrograde movement is one in which ubiquitina-
tion is a requisite event preceding the initiation of retro-
grade movement, with this covalent modification serving
to facilitate association with proteasomes and subsequent
entry into protein conducting channels. However, there
are observations with both TCR-a and CD3-d that make
such a simple model untenable. First, TCR-a has no
lysines within its short cytoplasmic tail (41), necessitating
cytoplasmic exposure of transmembrane and luminal lysines
to serve as sites of ubiquitination. Second, when all of the
cytoplasmic lysines of CD3-d were mutated and this pro-
tein was transiently expressed in non-T cells, TCR-a was
still subject to ubiquitination while associated with the ER
(Yang, Y., J.S. Bonifacino, and A.M. Weissman, unpub-
lished observations). These findings strongly suggest that
for both TCR-a and for CD3-d initiation of retrograde
transport can precede ubiquitination.
Since the steady state level of ubiquitinated forms are
low relative to the total number of molecules subject to
degradation, and initiation of retrograde movement can
precede ubiquitination, what then is the significance of
ubiquitination in degradation from the ER? First, we point
out that in most instances, when proteasome function is in-
hibited, proteins that are known to be ubiquitinated accu-
mulate primarily in non-ubiquitinated forms. This is due,
at least in part, to the ongoing activity of cellular deubiq-
uitinating enzymes (11). As there are no cell permeant se-
lective inhibitors of deubiquitinating enzymes, the percent
of TCR subunits that exist transiently in a ubiquitinated
form can not be determined. Since multiubiquitin chains
are potent proteasome targeting signals (11), ubiquitination
is required for the destruction of some ER membrane pro-
teins (12), and proteasomes are known to associate with the
ER (18, 52–54), we favor a model in which transmem-
brane proteins are predisposed for degradation from the ER
by either having never left, or reversibly entering, protein-
conducting channels, such as the translocon. In this hydro-
philic milieu they have the opportunity to undergo variable
degrees of movement across the membrane, enhancing
their susceptibility to ubiqutination. Ubiquitination leads to
association with 26S proteasomes, which facilitates com-
plete retrograde movement and degradation. Among pro-
teins, the relative requirements for ubiquitination and pro-844 Degradation of T Cell Receptor Subunits
teasomes in completing retrograde movement likely varies,
with human cytomegalovirus-enhanced loss of MHC class
I heavy chains at one end of the spectrum, and CD3-d at
the other. An alternative model that warrants consideration
is that proteasomes are drawn to translocons by ubiquiti-
nated chaperone-like translocon-associated proteins. This
facilitates the removal/degradation of target proteins that
are susceptible to retrotranslocation. For TCR subunits
there is no need to postulate such an indirect mechanism,
since TCR-a and CD3-d are both ubiquitinated. How-
ever, there is at least one in vitro situation where ubiquiti-
nation of calnexin has been suggested to facilitate the deg-
radation of a mutant form of a secreted protein (a1-
antitrypsin; reference 17).
When considering the enzymes responsible for the ubiq-
uitination of ER membrane proteins it is of note that two
yeast ubiquitin conjugating enzymes (E2s), UBC6 and
UBC7, have been implicated in the ubiquitination/degra-
dation of proteins from the ER (12, 55). One of these,
UBC6, has its catalytic domain localized to the cytoplasmic
face of the ER membrane through a hydrophobic COOH-
terminal anchor (28, 55). Interestingly, both of these E2s
are implicated in the ubiquitin-mediated degradation of
mutant forms of the Sec61 translocon complex (12), and
we now have evidence for the existence of an enzymati-
cally active mammalian UBC6 homolog (Tiwari, S., and
A.M. Weissman, unpublished observations).
Conclusion. Eukaryotic cells have evolved sophisticated
mechanisms to degrade both transmembrane and soluble
proteins of the secretory pathway that are either made in
excess or that are abnormally folded. It is apparent that
even among subunits of the TCR, multiple pathways exist
that ultimately lead to their breakdown by cytosolic protea-
somes. Degradation of CD3-d from the ER entails trim-
ming of mannose residues from N-linked oligosaccharides,
and recognition and proteolysis by proteasomes with con-
comitant removal from ER membranes. For TCR-a there
is no evidence that mannosidase activity plays a role, and a
significant degree of exposure of this protein to the cytosol
occurs regardless of proteasome function. Although light is
now being cast on what has been, until recently, a mysteri-
ous process, much remains to be learned regarding the mo-
lecular details of the multiple pathways leading to degrada-
tion from the ER.
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